APA (7th ed.) Citation

J, B., K, K., CY, C., R, B., JC, C., T, F., . . . MV, H. (2020). Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics. Science translational medicine, 12(549), . https://doi.org/10.1126/scitranslmed.aay6570

Chicago Style (17th ed.) Citation

J, Bovijn, et al. "Evaluating the Cardiovascular Safety of Sclerostin Inhibition Using Evidence from Meta-analysis of Clinical Trials and Human Genetics." Science Translational Medicine 12, no. 549 (2020). https://doi.org/10.1126/scitranslmed.aay6570.

MLA (9th ed.) Citation

J, Bovijn, et al. "Evaluating the Cardiovascular Safety of Sclerostin Inhibition Using Evidence from Meta-analysis of Clinical Trials and Human Genetics." Science Translational Medicine, vol. 12, no. 549, 2020, https://doi.org/10.1126/scitranslmed.aay6570.